dapagliflozin + empagliflozin + metformin

The combination of dapagliflozin, empagliflozin, and metformin refers to a therapeutic regimen used as the standard-of-care (SOC) comparator in clinical research conducted by Nazarbayev University. This specific combination is evaluated in adults with chronic heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) within the context of the study 'Metabolic Correction with GLP-1 in Cardiovascular Diseases in Kazakhstan'. Dapagliflozin and empagliflozin are sodium-glucose cotransporter 2 (SGLT2) inhibitors that reduce renal glucose reabsorption, promoting osmotic diuresis and providing cardiovascular protection. Metformin is a biguanide that primarily inhibits hepatic gluconeogenesis and improves insulin sensitivity. In the Nazarbayev University trial, this combination serves as the baseline therapy against which the efficacy and safety of dual GIP/GLP-1 receptor agonists, such as tirzepatide, are measured.

Other names

dapagliflozin + empagliflozin + metformin-Nazarbayev University-heart failure with preserved ejection fraction-type 2 diabetes mellitusStandard treatment (Nazarbayev University study)